Tags

Type your tag names separated by a space and hit enter

Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
Clin Infect Dis. 2005 Jul 15; 41 Suppl 2:S136-43.CI

Abstract

BACKGROUND

Intravenous-to-oral (iv/po) conversion is one cost-effective approach to the management of community-acquired pneumonia (CAP).

METHODS

Consecutive patients with CAP were enrolled during 3 study periods (January-March of 2001, 2002, and 2004) with different pharmacy intervention (PI) strategies: iv beta -lactam plus a macrolide (no PI), iv beta-lactam plus a macrolide with iv/po PI (PI switch), and iv moxifloxacin with pharmacist-initiated automatic po moxifloxacin conversion (PI sequential). Costs and outcomes were compared among groups.

RESULTS

Two hundred fifty-one patients were enrolled. The average Fine score was 75, and the mean age of patients was 51 years. In the PI groups, the duration of treatment with iv antibiotics was decreased. Clinical success on day 3 of therapy was improved in the PI sequential group but was similar in all 3 groups on day 7 of therapy and at the end of therapy. The length of stay in the hospital was similar for patients in all 3 groups (mean, 4.39 days). Antibiotic costs were significantly reduced, by $110/patient, in the PI sequential group.

CONCLUSIONS

Conversion from iv to po therapy was accomplished more quickly when converting to the same agent with pharmacist-initiated automatic iv/po conversion, thus reducing the associated cost without compromising efficacy.

Authors+Show Affiliations

Anti-Infective Research Laboratory, Wayne State University, Detroit, Michigan, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15942880

Citation

Davis, Susan L., et al. "Pharmacoeconomic Considerations Associated With the Use of Intravenous-to-oral Moxifloxacin for Community-acquired Pneumonia." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 41 Suppl 2, 2005, pp. S136-43.
Davis SL, Delgado G, McKinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis. 2005;41 Suppl 2:S136-43.
Davis, S. L., Delgado, G., & McKinnon, P. S. (2005). Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 41 Suppl 2, S136-43.
Davis SL, Delgado G, McKinnon PS. Pharmacoeconomic Considerations Associated With the Use of Intravenous-to-oral Moxifloxacin for Community-acquired Pneumonia. Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S136-43. PubMed PMID: 15942880.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. AU - Davis,Susan L, AU - Delgado,George,Jr AU - McKinnon,Peggy S, PY - 2005/6/9/pubmed PY - 2006/9/19/medline PY - 2005/6/9/entrez SP - S136 EP - 43 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 41 Suppl 2 N2 - BACKGROUND: Intravenous-to-oral (iv/po) conversion is one cost-effective approach to the management of community-acquired pneumonia (CAP). METHODS: Consecutive patients with CAP were enrolled during 3 study periods (January-March of 2001, 2002, and 2004) with different pharmacy intervention (PI) strategies: iv beta -lactam plus a macrolide (no PI), iv beta-lactam plus a macrolide with iv/po PI (PI switch), and iv moxifloxacin with pharmacist-initiated automatic po moxifloxacin conversion (PI sequential). Costs and outcomes were compared among groups. RESULTS: Two hundred fifty-one patients were enrolled. The average Fine score was 75, and the mean age of patients was 51 years. In the PI groups, the duration of treatment with iv antibiotics was decreased. Clinical success on day 3 of therapy was improved in the PI sequential group but was similar in all 3 groups on day 7 of therapy and at the end of therapy. The length of stay in the hospital was similar for patients in all 3 groups (mean, 4.39 days). Antibiotic costs were significantly reduced, by $110/patient, in the PI sequential group. CONCLUSIONS: Conversion from iv to po therapy was accomplished more quickly when converting to the same agent with pharmacist-initiated automatic iv/po conversion, thus reducing the associated cost without compromising efficacy. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/15942880/Pharmacoeconomic_considerations_associated_with_the_use_of_intravenous_to_oral_moxifloxacin_for_community_acquired_pneumonia_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/428054 DB - PRIME DP - Unbound Medicine ER -